Kidneys and bladder
76 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 10 GE Xenokidney for kidney failure, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AMDC-USR (iltamiocel) for urinary incontinence, stress | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apecotrep for glomerulosclerosis, focal segmental | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ARBs in combination of SGLT2i for proteinuria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arm 2A: TRACT/MONO mTOR for kidney failure, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arm 2B: TRACT/MONO CNI for kidney failure, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atrasentan for proteinuria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7760 for kidney failure, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belantamab mafodotin for kidney failure, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bepirovirsen for renal insufficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bladder Transplantation for renal insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Botulinum toxin type a for urinary bladder, overactive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Botulinum toxin type a for urinary incontinence | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivekimig for glomerulosclerosis, focal segmental | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivekimig for nephrosis, lipoid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cagrilintide for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ChoironeX GalKO Porcine Thymokidney for kidney failure, chronic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cilastatin for acute kidney injury | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cilastatin sodium for acute kidney injury | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined Kidney and Bladder Transplantation for renal insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Concomitant Renal and Urinary Bladder Allograft Transplantation for bladder exstrophy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Concomitant Renal and Urinary Bladder Allograft Transplantation for renal insufficiency, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Concomitant Renal and Urinary Bladder Allograft Transplantation for urinary bladder neck obstruction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Droxidopa for acute kidney injury | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elasomeran for renal insufficiency, chronic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for kidney failure, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney + Kidney Transplantation with Standard Care for kidney failure, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Frexalimab for glomerulosclerosis, focal segmental | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Frexalimab for nephrosis, lipoid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GGTA1 KO Thymokidney for kidney failure, chronic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Heparin for cystitis, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HRS-1780 tablets for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IGT-303 for renal insufficiency, chronic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for kidney diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iptacopan for proteinuria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JADE101 for proteinuria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lidocaine for cystitis, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for albuminuria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN + GALLIUM GA-68 GOZETOTIDE for renal insufficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Melatonin for ureteral calculi | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MSCs for renal insufficiency, chronic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MT1013 for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare for renal insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Paxlovid for uremia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for glomerulosclerosis, focal segmental | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + SOTAGLIFLOZIN for albuminuria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for albuminuria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for kidney failure, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rilzabrutinib for glomerulosclerosis, focal segmental | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rilzabrutinib for nephrosis, lipoid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Semaglutide + Cagrilintide for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium zirconium cyclosilicate for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| solifenacin combined with gabapentin for urinary bladder, overactive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| standard care + rotigotine at 4 mg/24h for 24 months. for kidney diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Suzetrigine for urinary incontinence, stress | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tenofovir Alafenamide Citrate for renal insufficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Testosterone for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ticagrelor for renal insufficiency, chronic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for renal insufficiency, chronic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tolvaptan for polycystic kidney, autosomal recessive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tozinameran for renal insufficiency, chronic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UKidney for kidney failure, chronic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Upacicalcet for renal insufficiency, chronic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Virtual Weight Management Coaching + Semaglutide for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| VNX001 for cystitis, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VX-407 for polycystic kidney, autosomal dominant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YOLT-203 for kidney calculi | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zigakibart for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziltivekimab for renal insufficiency, chronic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |